ClinicalTrials.Veeva

Menu

Pruritus and Pemphigoid in Nursing Home Patients (SSENIOR)

M

M.F. Jonkman

Status

Completed

Conditions

Pemphigoid
Pruritus

Treatments

Other: Blood sample

Study type

Observational

Funder types

Other

Identifiers

NCT02823067
NTR5843 (Registry Identifier)
NL56232.042.15
METc 2015/605 (Other Identifier)

Details and patient eligibility

About

The primary objective of this observational study is to describe the prevalence of pruritus and pemphigoid in nursing home patients. Secondary outcomes are the relationships of demographic factors and medical risk factors with pemphigoid, including dementia and neuropsychiatric symptoms, medication use and Karnofsky score.

Full description

Pruritus or itch is the most common skin symptom in elderly patients and is estimated to affect more than 30% of nursing home patients. Clinical and experimental evidence suggests pruritus in elderly patients may be linked to pemphigoid. Pemphigoid is the most common autoimmune skin blistering diseases and mainly affects the elderly. It is successfully treatable with systemic therapy. However, pemphigoid is often missed as a cause of pruritus in elderly patients (nonbullous cutaneous pemphigoid). Although nursing home patients and patients with dementia in particular have the highest risk for development of pemphigoid, no study has been performed in this population so far. Including serological screening for pemphigoid in the diagnostic evaluation of chronic pruritus in nursing home patients may lead to the diagnosis of pemphigoid. Furthermore, chronic itch may be an unrecognized cause of neuropsychiatric symptoms in nursing home patients with dementia.

Enrollment

125 patients

Sex

All

Ages

65+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Inpatient of a nursing home
  • Age 65 years or above
  • Subject or their official representatives have signed informed consent

Exclusion criteria

  • Age below 65 years
  • Subjects who do not have signed informed consent
  • Receiving treatment with any systemic immunosuppressive agents
  • Terminally ill patients with a life expectancy of less than 4 weeks

Trial design

125 participants in 1 patient group

Nursing home patients
Description:
Nursing home patients aged 65 years or above. One extra blood sample of 10 ml will be taken during a routine venapunction for immunoserology testing.
Treatment:
Other: Blood sample

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems